vom Dahl J, Altehoefer C, Büchin P, Sheehan F H, Schwarz E R, Koch K C, Schulz G, Uebis R, Schöndube F, Messmer B J, Büll U, Hanrath P
Medizinische Klinik I der RWTH Aachen, Universitätsklinikum Aachen.
Z Kardiol. 1996 Nov;85(11):868-81.
One hundred and sixty-one consecutive patients (144 male, 57 +/- 9 years) with stable coronary artery disease underwent nuclear imaging for assessment of myocardial viability using Tc-99m sestamibi single-photon emission computed tomography (SPECT) and F-18 fluoro-deoxy-glucose (FDG) positron emission tomography (PET). 88% had a history of chronic myocardial infarction and all had angiographically proven regional wall motion (RWM) abnormalities in the distribution territory of a stenosed or occluded coronary artery. Patients were followed for 29 +/- 6 (22-44) months with 84/161 patients (52%) receiving elective revascularization by either bypass surgery or angioplasty. 61/84 patients underwent follow-up angiography after 5 +/- 2 months for quantitative assessment of RWM changes using serial analysis with the centerline method in 45 pts with technically suitable paired angiograms. Myocardial regions were classified according to semiquantitative analysis of regional sestamibi and FDG uptake as either normal, regions with evidence for maintained viability but no mismatch ("mild match"), regions with a perfusion/metabolism "mismatch," or scar. RWM improved in "mismatch" regions from -2.2 +/- 1.0 SD to -1.0 +/- 1.4 SD (p < 0.01) compared to the mean of a normal reference population. In contrast, in regions with a "mild match" or those classified as scar, RWM analysis revealed no functional changes at follow-up. For the assessment of clinical outcome, patients were divided into three groups depending on the result of viability imaging. Those with predominantly scar tissue in the target region for viability assessment (group A, n = 90), those with a "mild match" (B, n = 26), and group C (n = 45) consisting of patients with a "mismatch" pattern. Subsequent treatment was not blinded to nuclear imaging results and revascularization was performed in 30% of group A (group A2), 81% of group B, and 80% of group C, while the other patients were treated medically only. Cardiac events during follow-up were defined as cardiac death, myocardial infarction, unstable angina with subsequent revascularization, cardiac transplantation, and survived resuscitation without evidence for myocardial infarction. Group C demonstrated a significant reduction of cardiac events from 22% to 0% following revascularization, whereas in group A coronary revascularization did not influence the frequency of events. Subjective assessment of angina pectoris and heart failure symptoms revealed more patients with improvement following revascularization as compared to those treated medically. Thus, combined nuclear imaging using sestamibi SPECT and FDG PET with quantitative tracer uptake analysis allows detection of absent or preserved myocardial viability in regions with reduced perfusion and function with prognostic implication for regional myocardial functional outcome as well as for identification of patients who benefit most from coronary revascularization.
161例连续的稳定型冠状动脉疾病患者(144例男性,年龄57±9岁)接受了核成像检查,以使用锝-99m甲氧基异丁基异腈单光子发射计算机断层扫描(SPECT)和氟-18氟代脱氧葡萄糖(FDG)正电子发射断层扫描(PET)评估心肌存活性。88%的患者有慢性心肌梗死病史,且所有患者在狭窄或闭塞冠状动脉的分布区域均有血管造影证实的局部室壁运动(RWM)异常。患者随访29±6(22 - 44)个月,161例患者中有84例(52%)接受了搭桥手术或血管成形术的择期血运重建。84例患者中的61例在5±2个月后接受了随访血管造影,以使用中心线法对45例技术上合适的配对血管造影进行系列分析来定量评估RWM变化。根据区域甲氧基异丁基异腈和FDG摄取的半定量分析,心肌区域被分类为正常、有存活证据但无不匹配的区域(“轻度匹配”)、有灌注/代谢“不匹配”的区域或瘢痕。与正常参考人群的平均值相比,“不匹配”区域的RWM从-2.2±1.0标准差改善至-1.0±1.4标准差(p<0.01)。相比之下,在“轻度匹配”区域或被分类为瘢痕的区域,RWM分析显示随访时无功能变化。为了评估临床结局,根据存活性成像结果将患者分为三组。在存活性评估的目标区域主要为瘢痕组织的患者(A组,n = 90),有“轻度匹配”的患者(B组,n = 26),以及由有“不匹配”模式的患者组成的C组(n = 45)。后续治疗未对核成像结果设盲,A组30%(A2组)、B组81%和C组80%的患者接受了血运重建,而其他患者仅接受药物治疗。随访期间的心脏事件定义为心源性死亡、心肌梗死、随后接受血运重建的不稳定型心绞痛、心脏移植以及存活的复苏且无心肌梗死证据。C组在血运重建后心脏事件从22%显著降低至0%,而在A组冠状动脉血运重建并未影响事件发生频率。对心绞痛和心力衰竭症状的主观评估显示,与接受药物治疗的患者相比,血运重建后更多患者症状改善。因此,使用甲氧基异丁基异腈SPECT和FDG PET联合核成像及定量示踪剂摄取分析能够检测灌注和功能降低区域心肌存活性的缺失或保留情况,对区域心肌功能结局具有预后意义,同时也有助于识别从冠状动脉血运重建中获益最大的患者。